In Re Zyprexa Products Liability Litigation

424 F. Supp. 2d 488, 2006 WL 768673
District Court, E.D. New York·Decided March 28, 2006·No. 2:04-cv-01596·Published·Cited by 31 cases

Opinion

MEMORANDUM & ORDER ON FEES

WEINSTEIN, Senior District Judge.

Table of Contents

I. Introduction...............................................................490

II. Procedural History.........................................................490

*490 III. Fee Allocation...................... ......................................490

IV. Basis of Authority in Federal Courts .. ......................................491

A. Analogy to Class Actions......... ......................................491

B. General Ethical Supervision...... ......................................492

1. Law....................... ......................................492

2. Application of Law to Facts ... ......................................493

V.Parallel State Law.................. ......................................494

VI.Conclusion......................... ......................................496

I. Introduction

By this order the court exercises its power to control legal fees in a coordinated litigation of many individual related cases — in effect, á quasi-class action. Limiting fees is particularly appropriate in the instant litigation since much of the discovery work the attorneys would normally have done on a retail basis in individual cases has been done at a reduced cost on a wholesale basis by the plaintiffs’ steering committee.

II. Procedural History

In April 2004, pre-trial proceedings were consolidated in actions against defendant Eli Lilly & Company for injuries alleged to have been caused by the prescription drug Zyprexa. See letter of April 14, 2004 from the Multidistrict Litigation Panel to the Clerk of the Eastern District of New York. After discovery and negotiations overseen by the court-appointed special discovery master and four special settlement masters, in November 2005 the defendant entered into a partial settlement covering some 8,000 individual plaintiffs. See In re Zyprexa Prod. Liab. Litig., No. 04-MD-1596, 2005 WL 3117302 (E.D.N.Y. Nov. 22, 2005) (approving settlement). Under court supervision, a complex claims administration process was developed. It will be administered by the special settlement masters. Id. Three different “tracks” for recovery are provided. The track selected depends on the nature of each plaintiffs injury and the estimated monetary value of the claim. Track A provides for a lump sum of $5,000. Tracks B and C allow substantially higher recoveries. Id.

III.Fee Allocation

On January 3, 2006, the four settlement special masters were directed to consult with the parties in order to arrive at a recommended fee schedule cap and allocation of expenses. See In re Zyprexa Prod. Liab. Litig., 233 F.R.D. 122 (E.D.N.Y. 2006). They were to suggest fees which were “the lesser of the maximum reasonable fee schedule they recommend, the fee agreed upon between the client and the attorney in an individual case, and the maximum amount permitted under the applicable local state rules or statutes.” Id. at 122.

Upon consultation with counsel and with members of the plaintiffs’ steering committee, the special masters proposed that the court: (1) cap all legal fees for “Track A” settlements ($5,000) at no more than 20%, with a maximum of $500 for costs and expenses to come off the top before computation of fees; (2) cap all other fees at 37.5% of recovery; and (3) work with the firms representing the settling plaintiffs to conduct case-by-case evaluations that might result in further changes in fee caps or allocation of expenses because of “unique circumstances.” See letter of March 7, 2006 from special settlement *491 master Kenneth R. Feinberg on behalf of the four special settlement masters.

After careful consideration of the complicated and exceptional circumstances posed by this case, this court now adopts the special masters’ proposal with two main modifications. First, the court reduces the cap from 37.5% to 35%. Second, in order to guarantee that all attorneys receive adequate but not excessive compensation, the special masters will have the power to vary fee caps upwards to a maximum of 37.5% and downward to 30% in individual eases on the basis of special circumstances; clients and attorneys may appeal to the court from any such adjustments. The special settlement masters will supervise the allocation of costs and expenses in individual cases; they will be limited to those incurred in individual cases, except for Track A cases where there is a cap of $500 as stated above.

The costs of the plaintiffs’ steering committee in conducting general discovery and making documents and depositions available to all litigants, whether in federal or state courts, shall be paid out of the general settlement fund, not by individual plaintiffs. This allocation is particularly apt in the present case since all litigants, whether in federal or any state court, have access to the materials obtained in pretrial discovery. See In re Zyprexa Prod. Liab. Litig., 04-MD-1596, 2004 WL 3520248, at *4 (E.D.N.Y. Aug.18, 2004). See also letter dated January 30, 2006 to state court judges with Zyprexa cases from assigned federal judge suggesting coordination and cooperation. The amount to be paid to the plaintiff's steering committee for its discovery and other work shall be approved by the special settlement masters.

In carrying out their duties under this order, the special settlement masters shall act as a group, not individually.

IV. Basis of Authority in Federal Courts
A. Analogy to Class Actions

A district court has the explicit power to require reasonable fees in class actions. See Fed.R.Civ.P. 23(g)(l)(C)(iii); Fed.R.Civ.P. 23(h); of. Fed.R.Civ.P. 23(e)(l)-(2) (dealing with approval of terms of settlement). See also In re “Agent Orange’’ Prod. Liab. Litig., 611 F.Supp. 1296 (E.D.N.Y.1985). While the settlement in the instant action is in the nature of a private agreement between individual plaintiffs and the defendant, it has many of the characteristics of a class action and may be properly characterized as a quasi-class action subject to general equitable powers of the court. See Fed.R.Civ.P. 23(g)(C)(iii); Fed.R.Civ.P. 23(h); Fed. R.Civ.P. 1. (“just ...

Free access — add to your briefcase to read the full text and ask questions with AI

In Re Zyprexa Products Liability Litigation, 424 F. Supp. 2d 488, 2006 WL 768673 (E.D.N.Y. 2006).

424 F. Supp. 2d 488 (In Re Zyprexa Products Liability Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Andrews v. Blick Art Materials, LLC
286 F. Supp. 3d 365 (E.D. New York, 2017)
Cirino v. City of New York
754 F.3d 114 (Second Circuit, 2014)
Jane Doe 30's Mother v. Bradley
64 A.3d 379 (Superior Court of Delaware, 2012)
Sullivan v. DB Investments, Inc.
619 F.3d 287 (Third Circuit, 2011)
Lewis v. City of New York
689 F. Supp. 2d 417 (E.D. New York, 2010)
In Re Zyprexa Products Liability Litigation
594 F.3d 113 (Second Circuit, 2010)
Hood ex rel. Mississippi v. Eli Lilly & Co.
671 F. Supp. 2d 397 (E.D. New York, 2009)
Earl v. Eli Lilly & Co.
688 F. Supp. 2d 130 (E.D. New York, 2009)
In Re Zyprexa Products Liability Litig.
688 F. Supp. 2d 130 (E.D. New York, 2009)
In Re Zyprexa Products Liability Litigation
649 F. Supp. 2d 18 (E.D. New York, 2009)
Head v. Eli Lilly & Co.
649 F. Supp. 2d 18 (E.D. New York, 2009)
In Re Vioxx Products Liability Litigation
574 F. Supp. 2d 606 (E.D. Louisiana, 2008)
United States v. Overseas Shipholding Group, Inc.
547 F. Supp. 2d 75 (D. Massachusetts, 2008)